Research and development - Today Stories

The Thermo Scientific iCAP RQplus ICP-MS Analyzer and the Thermo Scientific iSC-65 Autosampler Enable Easy, Accurate Analysis of High Matrix Samples Thermo Fisher Scientific has introducedthe Thermo Scientific iCAP RQplus ICP-MS Analyzer, a new trace elemental analyzer that simplifies everyday analyses in environmental, food, pharmaceutical and industrial testing laboratories. The company also introduced the Thermo Scientific iSC-65 Autosampler to improve productivity for the Thermo Scientific iCAP Qnova Series ICP-MS analyzer and the Thermo Scientific iCAP PRO Series ICP-OES. The new Thermo Scientific iCAP RQplus ICP-MS Analyzer (left) provides the operational simplicity and stability that laboratories require for ongoing daily analysis of trace elements at low concentrations in a wide ra…

Bagsværd, Denmark, 2 March 2023 – Novo Nordisk just announced plans to expand its research and development (R&D) presence in the greater Boston metro area, creating one of its largest R&D hubs outside of Denmark. This new hub, which will leverage the company’s existing presence in Lexington, Cambridge and Watertown, Massachusetts, will be home to the majority of Novo Nordisk’s US-based research and development activities.   Novo Nordisk anticipates adding more than 200 new jobs in the Boston area in 2023. Of these new positions, more than 150 will be lab-based and clinical development personnel in Lexington and Watertown and involved in data science, biology or chemistry research, and ribonucleic acid interference (RNAi) research and clinical development.    “The Boston area is the…

COPENHAGEN, Denmark, March 1, 2023 – BioInnovation Institute (BII), an international non-profit foundation incubating and accelerating world-class life science research, today announces that ten new companies have entered its Venture Lab acceleration program for early-stage companies. The cohort is strategically aligned with BII’s focus on supporting innovative early-stage start-ups within human and planetary health. The 12-month Venture Lab program is designed to support start-up companies with business acceleration, scientific, and team development, and provides a founder-friendly convertible loan of EUR 500,000 (approximately 4M DKK) plus access to labs and offices at the BII in Copenhagen. In becoming a part of the Venture Lab program, the early-stage companies also get an exclusive op…

-  Partnership Combines AbbVie's extensive capabilities with Capsida's novel adeno-associated virus (AAV) engineering platform -  Builds upon the neurodegenerative disease partnership announced in 2021 NORTH CHICAGO, Ill. and THOUSAND OAKS, Calif., Feb. 23, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Capsida Biotherapeutics Inc. ("Capsida") today announced an expanded strategic collaboration to develop genetic medicines for eye diseases with high unmet need. AbbVie's extensive capabilities will be paired with Capsida's novel adeno-associated virus (AAV) engineering platform and manufacturing capability to identify and advance three programs. The collaboration builds upon the neurodegenerative disease partnership announced in 2021. "This expanded collaboration with Capsida has the potentia…

EDX Medical Group plc, (“EDX Medical” or the “Company”), which develops innovative digital diagnostic products and services for cancer, heart disease, neurology and infectious disease testing, today announces that it has acquired Torax Biosciences Ltd., a research company providing product development and pilot scale fabrication of immune-assays and diagnostic testing solutions. Torax becomes a wholly-owned subsidiary of EDX Medical and will provide an experienced point-of-care diagnostics technical team with proven skills in innovation and new product development. Torax will also provide additional UK laboratory capacity in Northern Ireland in support of EDX’s established laboratories in Cambridge. The Torax business operates under ISO 9001 and ISO-13485 accredited quality systems for IVD…

Cambridge and Cardiff, UK, 13 February 2023, Astex Pharmaceuticals (UK) (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system and The Medicines Discovery Institute, Cardiff University (“MDI”) announced today that they have entered into a multi-year, multimillion pound drug discovery research collaboration, aimed to identify new drugs to treat neurodegenerative diseases.   The collaboration brings together the world-leading research expertise of Dr Emyr Lloyd-Evans & Dr Helen Waller-Evans in lysosomal biology, the drug discovery capabilities of the MDI and the fragment-based drug discovery platform at Astex. The combined teams will focus on identifying compounds which mo…

2cureX, a company pioneering the use of 3D tumoroids for drug sensitivity prediction in patients with cancer, announced today the signature of an IndiTreat® distribution agreement for Switzerland and Austria with pedoc Medical. At the same time, the company unveiled the decision to include Iceland in their Nordic direct operations. IndiTreat is now actively promoted in 20 countries in Europe and the Middle East – reaching the stated geographic rollout goal for 2022. Entering the attractive Swiss and Austrian IVD markets 2cureX and pedoc Medical have signed an agreement by which pedoc Medical becomes the distributor of IndiTreat® products in Switzerland and Austria. Under the terms of the collaboration, pedoc Medical will promote IndiTreat® to oncology professionals, sign supply agreements…

Today, Novozymes and Chr. Hansen have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies. The combination is expected to unleash the full potential of biological solutions and generate significant value for all stakeholders and society at large. COPENHAGEN, Denmark – December 12, 2022. The proposed combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") will create a strong biosolutions group with a broad biological toolbox and a diversified portfolio across markets. Uniting two strategically complementary biosolutions companies will accelerate their already best-in-class performance. Novozymes and Chr. Hansen together will meet customers’ growing demands for efficient, scalable, and susta…

Research & Development (R&D) jobs are the most in-demand across the Life Sciences sector with vacancies up 5% year-on-year. That’s according to new research from the Association of Professional Staffing Companies (APSCo), the trade association for the professional staffing sector. According to the data, provided by business intelligence specialist Vacancysoft, R&D jobs across the UK are predicted to reach 4,218 by the end of 2022 and now account for 34% of jobs posted within the Life Sciences arena. When analysing the data by region, it’s perhaps no surprise that the biggest concentration of jobs was noted across the South East, with vacancies hitting over 3,000 year-to-date. By contrast, the research reveals that Yorkshire and the Humber could see the most considerable decreas…

EDX Medical Group plc, (“EDX Medical” or the “Company”), which develops innovative digital diagnostic products and services for cancer, heart disease, neurology and infectious disease testing, today announces a collaborative cancer biomarker programme that will improve access to cost-effective and reliable tests for a range of cancers in the UK and Europe. The programme is a result of a partnership between the Company and Tianjin Bioscience Diagnostic Technology Co. Ltd (“Bioscience”), an internationally active, ISO 13485-certified research-based manufacturer of diagnostic products and reagents. The Company has been selected by Bioscience as its lead partner to validate and commercialise its suite of internationally recognised cancer biomarkers in Europe. The programme will encompass the v…

World antibiotic awareness week 18 to 25 November 2022 In 2019, it was estimated that 1.2 million deaths globally, were due to antibiotic-resistant infections1. In England, during 2019/20, there were over 90,000 hospital admissions2 – yet the global pipeline for new antibiotics to address this growing problem has been failing. This year’s World Antimicrobial Awareness Week aims to improve the awareness and understanding of antimicrobial resistance (AMR). The event seeks to encourage best practices among the public, health workers and policy makers to avoid the further emergence and spread of antibiotic resistance. We are now living in an age where drug resistant microbes are developing faster than new antimicrobial treatments, which poses a huge threat to modern medicine. Amit Aggarwal, Ex…

Brandon Capital announces its participation in NRG Therapeutics’ £16 million (AUD$29m) Series A alongside Omega Funds NRG is developing inhibitors of a first-in-class target as a potential disease-modifying treatment for Parkinson's and Amyotrophic Lateral Sclerosis (ALS), also known as motor neurone disease (MND) towards the clinic The financing enables UK-headquartered NRG Therapeutics to expand its research team in Australia led by Prof Seth Masters under an agreement with WEHI (Walter and Eliza Hall Institute of Medical Research) Jonathan Tobin, Partner at Brandon Capital, joins the NRG board; and Prof Masters joins the management team as VP Discovery Biology Melbourne, Australia and London UK, 9 November 2022 – Brandon Capital, Australasia’s leading life science venture capital firm…

LEIDEN, The Netherlands, November 02, 2022 / B3C newswire / -- MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position. Henk Volberda, chairman of the jury and professor of Strategy & Innovation at the University of Amsterdam: “MIMETAS is world-leading. Since its foundation in 2013, the company has grown considerably, with branches in Europe, the USA, and Asia. It can now count the largest pharmaceutical companies worldwide among its partners. With its miniaturized organs-on-a-chip, MIMETAS has found a promising approach to enable major advancements in the pharmaceutical industry.” “The…

Expands Specialty Diagnostics Segment with Industry Leader in Oncology Testing for Detection and Monitoring of Multiple Myeloma Complements Existing Specialty Diagnostics Offering with Established Technologies Delivering Strong Clinical Value for Patients in a Rapidly Growing Diagnostics Segment WALTHAM, Mass.--(BUSINESS WIRE)-- Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”), the world leader in serving science, today announced that it has entered into a definitive agreement to acquire The Binding Site Group (“The Binding Site”), a global leader in specialty diagnostics, from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.25 billion, or $2.6 billion at current exchange rates. Serving clinicians and laboratory pro…

GENERATION OF LONGITUDINAL PANOMICS DATA TO IMPROVE THE DISEASE UNDERSTANDING OF SJÖGREN’S SYNDROME (“SJS”) AND SYSTEMIC LUPUS ERYTHEMATOSUS (“SLE”) HANNOVER MEDICAL SCHOOL (“MHH”) WILL COLLECT BIOSAMPLES FROM SJS AND SLE PATIENTS EVOTEC WILL LEVERAGE ITS UNIQUE PANOMICS TECHNOLOGIES TO IMPROVE PATIENT STRATIFICATION AND CREATE NEW ENTRY POINTS FOR PRECISION MEDICINE DRUG DISCOVERY Hamburg, Germany, 25 October 2022:Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that the Company has entered a partnership with Hannover Medical School (“MHH”), one of the leading German universities, to generate a molecular patient database for Sjögren’s syndrome (“SjS”) and systemic lupus erythematosus (“SLE”).The strategic partnership between Evotec…

Collaboration leverages one of world’s largest sources of de-identified patient data to accelerate drug discovery, initially in oncology Access will enable GSK to improve clinical trial design, speed up enrolment and identify drug targets GSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK with access to Tempus’ AI-enabled platform, including its library of de-identified patient data. Through its leading Artificial Intelligence and Machine Learning (AI/ML) capability, GSK will work together with Tempus to improve clinical trial design, speed up enrolment and identify drug targets. This will contribute to GSK’s R&D success rate and provide patients with more personalised treatment faste…

New facility adds supply assurance and capacity to enable more life-saving vaccines and therapies WALTHAM, Mass., September 20, 2022 – Thermo Fisher Scientific Inc., the world leader in serving science, today opened a new biomanufacturing facility in Chelmsford, Massachusetts. The $160 million, 85,000-square-foot facility will help meet growing demand for the biologic materials needed to produce vaccines and breakthrough therapies for cancer and other diseases. This new site is part of Thermo Fisher’s $650 million multi-year investment to expand its bioprocessing production capabilities. The technologies produced at the Chelmsford site are used in the purification process of developing biotherapeutics and vaccines. These products help save time and reduce costs so that new treatments ca…

NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, today announced its partnership with TMA Precision Health, a company on a mission to improve the lives of rare disease patients everywhere, offering clinical whole genome sequencing to rare disease patients as the first step in diagnosing and treating disease with more personalized medicine. “The simple act of providing a whole genome sequence is likely the single most important piece of healthcare for a patient with a rare disease, and no child or family should have to needlessly suffer because they can’t afford it,” said Joshua Resnikoff, CEO and Cofounder of TMA Precision Health. “Our mission is to bring this service to those that need it most. We are thrilled to partner with…

Radiology technology start-up Hexarad has completed its Series A funding round with an additional raise of £2.2 million. This is in addition to £2.3 million Hexarad raised in 2021, bringing the full raise to £4.5 million. The round was led by Foresight Group, the leading private equity and infrastructure investment manager, who also invested in 2021, with additional participation from angel investors including healthcare leaders Sachin Agrawal based in the US and Henry Carleton based in the UK. Hexarad is an early stage, high growth healthcare technology company, providing technology-driven solutions to boost radiology capacity and address the key causes of diagnostic delays. Headquartered in London, Hexarad was founded in 2016 by a group of NHS consultant radiologists. Since 2016, Hexarad…

Epredia, a global leader in precision cancer diagnostics, today announced that its parent company PHC Holdings Corporation [TSE 6523] has acquired anatomical pathology suppliers Microm Microtech France (MMFrance) and Laurypath in a strategic expansion of Epredia’s presence in Europe. MMFrance and Laurypath, both founded in 1987 in Lyon, France, manufacture and supply anatomical pathology products and provide services for laboratories throughout France, offering high levels of technical support and a local supply of reagents and other consumables used in cancer diagnostics. Both companies will now operate as fully owned subsidiaries of PHC Holdings Corporation (PHC Group). With this acquisition, Epredia now adds Laurypath’s European-based manufacturing of tissue processing reagents and f…